Sanofi SA

Chart & Performance

D1W1MN

P/E

11.13

P/S

1.40

EPS

4.44

Div Yield, %

4.02%

Shrs. gr., 5y

-13.00%

Rev. gr., 5y

3.31%

Revenues

44.29b

-3.80%

Net income

5.56b

+2.96%

CFO

9.08b

-11.47%

Dividend

May 09, 20242.19782 USD/sh

Earnings

Apr 30, 2025

Profile

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

URL

https://www.sanofi.com/

IPO date

Jul 01, 2002

Employees

91,573

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	44,286,000 -3.80%	46,033,000 1.42%	45,389,000 15.86%
Cost of revenue	20,599,000	20,964,000	20,401,000
Unusual Expense (Income)
NOPBT	23,687,000	25,069,000	24,988,000
NOPBT Margin	53.49%	54.46%	55.05%
Operating Taxes	1,204,000	1,602,000	2,006,000
Tax Rate	5.08%	6.39%	8.03%
NOPAT	22,483,000	23,467,000	22,982,000
Net income	5,560,000 2.96%	5,400,000 -35.49%	8,371,000 34.52%
Dividends	(4,704,000)	(4,454,000)	(4,168,000)
Dividend yield	4.00%	3.95%	1.85%
Proceeds from repurchase of equity	(115,000)	(398,000)	(309,000)
BB yield	0.10%	0.35%	0.14%
Debt
Debt current	4,470,000	2,320,000	4,451,000
Long-term debt	15,342,000	18,132,000	18,942,000
Deferred revenue			7,801,000
Other long-term liabilities	10,177,000	9,958,000	1,193,000
Net debt	8,626,000	8,485,000	7,228,000
Cash flow
Cash from operating activities	9,081,000	10,258,000	10,526,000
CAPEX	(3,195,000)	(3,253,000)	(2,201,000)
Cash from investing activities	(4,407,000)	(6,200,000)	(2,075,000)
Cash from financing activities	(5,763,000)	(8,052,000)	(5,821,000)
FCF	12,261,000	23,857,000	23,744,000
Balance
Cash	7,927,000	8,710,000	13,400,000
Long term investments	3,259,000	3,257,000	2,765,000
Excess cash	8,971,700	9,665,350	13,895,550
Stockholders' equity	73,437,000	75,224,000	137,809,000
Invested Capital	96,968,300	93,067,650	90,468,450
ROIC	23.66%	25.57%	25.69%
ROCE	21.91%	23.97%	23.53%
EV
Common stock shares outstanding	1,253,000	1,256,400	2,513,800
Price	93.74 4.43%	89.76 -0.09%	89.84 1.42%
Market cap	117,456,220 4.15%	112,774,464 -50.06%	225,839,782 1.34%
EV	126,432,220	121,572,464	233,435,782
EBITDA	27,273,000	28,845,000	28,408,000
EV/EBITDA	4.64	4.21	8.22
Interest	749,000	1,094,000	472,000
Interest/NOPBT	3.16%	4.36%	1.89%